

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization  
International Bureau(43) International Publication Date  
9 October 2003 (09.10.2003)

PCT

(10) International Publication Number  
**WO 03/082215 A2**(51) International Patent Classification<sup>7</sup>: **A61K**(21) International Application Number: **PCT/US03/09766**

(22) International Filing Date: 27 March 2003 (27.03.2003)

(25) Filing Language: English

(26) Publication Language: English



(30) Priority Data:  
60/367,790 27 March 2002 (27.03.2002) US  
60/416,414 7 October 2002 (07.10.2002) US(71) Applicant (for all designated States except US): **MEMO-  
RIAL SLOAN-KETTERING CANCER CENTER**  
[US/US]; 1275 York Avenue, New York, NY 10021-6007  
(US).

(72) Inventor; and

(75) Inventor/Applicant (for US only): **PASTERNAK,**Gavril, W. [US/US]; Apartment 21M, 500 East 83rd  
Street, New York, NY 10028 (US).(74) Agents: **LAWRENCE, William, F.** et al.; Frommer  
Lawrence & Haug LLP, 745 Fifth Avenue, New York, NY  
10151 (US).(81) Designated States (*national*): AE, AG, AL, AM, AT, AU,  
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU,  
CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,  
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,  
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW,  
MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE,  
SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ,  
VC, VN, YU, ZA, ZM, ZW.(84) Designated States (*regional*): ARIPO patent (GH, GM,  
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW),  
Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),  
European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE,  
ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO,

[Continued on next page]

(54) Title: SYNERGISTIC L-METHADONE COMPOSITIONS AND METHODS OF USE THEREOF



(57) Abstract: The present invention relates to pharmaceutical compositions and methods wherein L-methadone and at least one other opioid analgesic are administered in amounts effective to potentiate a synergistic antinociceptive response to moderate and severe pain, preferably with decreased dependence and tolerance potential. Synergistic potentiation of analgesia through administration of pharmaceutical compositions comprising L-methadone and at least one other opioid analgesic provides a new and improved approach to pain management.